Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy in High Risk Early HR+/HER2-breast Cancer Based on Molecular Marker

NCT05809024 is registered in ClinicalTrials.gov with Yongsheng Wang as lead sponsor.

NCT NCT05809024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05809024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy in High Risk Early HR+/HER2-breast Cancer Based on Molecular Marker
Lead sponsor
Yongsheng Wang
Phase
Phase 4
Overall status
Unknown status
Start date
March 1, 2023
Completion date
March 25, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone receptor positive，her2-negative breast cancer, locally advanced breast cancer